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Purpose: A great variety of studies on preoperative serum testosterone as a predictor 
of progression of prostate cancer have been reported recently. The purpose of this study 
was to investigate the relationship of preoperative serum testosterone levels in patients 
who underwent radical prostatectomy with prognostic factors.
Materials and Methods: Clinical data were collected from 60 patients who underwent 
radical prostatectomy. The 60 cases were divided into 2 groups according to their pre-
operative serum testosterone levels: group 1 (n=21), ＜3 ng/ml; group 2 (n=39), ≥3 
ng/ml. The groups were compared according to prog-ression factors. Multivariate logis-
tic regression analysis was performed to determine the correlation between bio-
chemical recurrence and each variable.
Results: The incidence of extraprostatic invasions was significantly higher in group 1 
with 13 cases in group 1 (61.9%) and 11 cases in group 2 (28.2%) (p=0.011). The incidence 
of biochemical recurrence was also significantly higher in group 1 with 5 cases in group 
1 (23.8%) and 2 cases in group 2 (5.1%) (p=0.032). A low serum testosterone level (≤3 
ng/ml) was associated with an increased risk of biochemical recurrence (odds ratio [OR], 
13.64; 95% confidence interval [CI], 1.66 to 2.43; p=0.015) and an increased risk of ex-
traprostatic invasions (OR, 4.96; 95% CI, 1.41 to 17.38; p=0.012).
Conclusions: The incidence rates of extraprostatic invasions and biochemical re-
currence were significantly higher in the group with preoperative average serum testos-
terone of less than 3 ng/ml. Therefore, these results suggest that preoperative average 
serum testosterone will be useful in predicting postoperative prostate cancer 
progression. 
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INTRODUCTION
Androgen is known to not only play essential roles in the 
growth and maintenance of the prostate but also be involved 
in the growth of prostate cancer cells [1]. Through animal 
experiments, Lucia et al. [2] found that prostate cancer is 
suppressed when androgen values in the body are reduced. 
In addition, many studies are currently being conducted to 
compare diverse stages of prostate cancer progression and 
related prognosis with androgen values [3]. It is known that 
preoperative average serum testosterone is associated 
with low rates of responses to treatment and poorer pro-
gression in metastatic prostate cancer and that, in partic-
ular, a preoperative average serum testosterone level of 3 
ng/ml or less is associated with short survival time and ad-
vanced disease [4]. Currently, although clinical stages, 
Gleason scores obtained from biopsies, and prostate-spe-
cific antigen (PSA) values are known to be markers for pre-
dicting post-radical-prostatectomy progression, the rela-
tionship between preoperative average serum testoster-
one and prognoses has not yet been clearly established. In 
this respect, we intended to examine the relationship be-
tween preoperative average serum testosterone and 
post-radical-prostatectomy prostate cancer progression in Korean J Urol 2012;53:9-13
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TABLE 1. Baseline characteristics of the study subjects
Characteristic Value
Age (yr) 
BMI (kg/m
2) 
PSA 
Clinical stage 
T1c (%)
T2a (%)
T2b (%)
T2c (%)
T3 (%)
Gleason score
≤6 (%)
7
≥8 (%)
Prostate volume (m/l) (range)
65.1 (52-74)
23.4 (18-24)
9.48 (2.45-20.3)
   27 (45.0)
   15 (25.0)
     9 (15.0)
     8 (13.3) 
     1 (1.6)
   29 (48.3)
   20 (33.3)
   11 (18.3)
37.7 (14-87)
Values are presented as mean±SD or number (%). 
BMI, body mass index; PSA, prostate-specific antigen.
patients who had undergone a radical prostatectomy.
MATERIALS AND METHODS
The subjects of this study were 60 patients in whom pre-
operative average serum testosterone was measured 
among 81 patients who were diagnosed with prostate can-
cer between January 2005 and December 2009 and under-
went a radical prostatectomy as the initial treatment. The 
average age of the patients was 65 years, the mean fol-
low-up period was 18 months (range, 2 to 48 months), and 
the preoperative average PSA was 9.48 ng/ml.
According to hospital records, the patients’ ages, body 
mass index (BMI), preoperative PSA, Gleason scores, pros-
tate volumes, extraprostatic invasions, seminal vesical in-
vasions, positive surgical margins, lymphovascular in-
vasions, perineural invasions, biochemical recurrence 
(BCR), and metastatic states were examined. Blood for 
measuring preoperative serum testosterone was collected 
in the morning when testosterone values are high and sta-
ble, and the values were measured by radioimmunoassay. 
BCR was defined as cases in which PSA measured 0.2 ng/ml 
or higher two times successively after the surgery. The 12 
core biopsy scheme used in our institution includes a stand-
ard sextant, which was originally described by Hodge et al. 
[5], as well as a lateral sextant scheme (lateral apex, lateral 
mid-gland, lateral base) [6]. The biopsy policy of our in-
stitution consists of an additional two core biopsies in cases 
of palpable nodules in the digital rectal examination or sus-
picious lesions in transrectal ultrasonography (TRUS). 
Biopsies were performed under ultrasound guidance by 
use of an 18 gauge, 2 cm, Trucut core needle biopsy, and 
pathological judgments of all tissues were made by two 
pathology boards. TRUS-guided prostate biopsy was per-
formed to assess individual biopsy cores for any existence 
of tumors and Gleason scores, and postoperative biopsies 
were performed to assess extraprostatic invasions, semi-
nal vesical invasions, positive surgical margins, lympho-
vascular invasions, and perineural invasions.
On the basis of a testosterone value of 3 ng/ml, the pa-
tients were divided into two groups [7,8]: 21 cases with 
preoperative average serum testosterone of less than 3 
ng/ml (35%), who were defined as group 1, and 39 cases 
with preoperative average serum testosterone of 3 ng/ml 
or more (65%), who were defined as group 2. Ages, BMI, 
Gleason scores, prostate volumes, extraprostatic in-
vasions, seminal vesical invasions, positive surgical mar-
gins, lymphovascular invasions, perineural invasions, BCR, 
and the existence of metastatic tumors were compared be-
tween the two groups.
Statistical analyses were performed by using SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA). Chi-square tests and 
student's t-tests were used to identify statistical differ-
ences between the two groups and multivariate logistic re-
gression analysis was performed to determine the correla-
tion between biochemical recurrence and each variable. In 
all analyses, cases in which p＜0.05 were considered to be 
statistically significant.
RESULTS
1. Patient characteristics 
The patients’ mean age was 65.1 years (range, 52 to 74 
years), their mean BMI was 23.4 kg/m
2 (range, 18 to 24 
kg/m
2), and their mean PSA was 9.48 ng/ml (range, 2.45 to 
20.3 ng/ml). The patients’ clinical stages included 27 cases 
of T1c (45%), 15 cases of T2a (25%), 9 cases of T2b (15%), 
8 cases of T2c (13.3%), and 1 case of T3 (1.6%). Gleason sco-
res obtained from biopsies included 29 cases of a Gleason 
score of 6 (48.3%), 20 cases of a score of 7 (33.3%), and 11 
cases of scores of 8 to 10 (18.3%), and the average prostatic 
volume was 37.7 ml (range, 16 to 87 ml) (Table 1).
2. Comparison of clinicopathologic features according to 
preoperative serum testosterone level
The values of average preoperative serum testosterone in 
group 1 and group 2 were 1.99 ng/ml and 5.02 ng/ml, re-
spectively, whereas no significant differences (p=0.628) 
were shown in the groups’ respective average ages of 66 and 
64 years (p=0.782) or BMI of 25.2 kg/m
2 and 25.5 kg/m
2. 
Mean PSA values were higher in group 1, 10.45 ng/ml in 
group 1 and 7.67 ng/ml in group 2 (p=0.031), whereas there 
was no significant difference in Gleason scores or average 
prostatic volumes between the two groups (p=0.726, 
p=0.793). The incidence of extraprostatic invasion was sig-
nificantly higher in group 1, 13 cases in group 1 (61.9%) and 
11 cases in group 2 (28.2%) (p=0.011), whereas there were 
no significant differences between the two groups in pos-
itive surgical margins, lymphovascular invasions, peri-
neural invasions, or seminal vesical invasions. The in-
cidence of BCR was higher in group 1, 5 cases in group 1 
(23.8%) and 2 cases in group 2 (5.1%) (p=0.032), whereas 
there were no significant differences in metastasis be-
tween the two groups, with 1 case each in each group (4.7%, Korean J Urol 2012;53:9-13
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TABLE 2. Comparison of clinicopathologic features according to preoperative serum testosterone level
Variable Group 1 (n=21) Group 2 (n=39) p-value
Age (yr)
BMI (kg/m
2)
Pretreatment PSA (ng/ml)
Prostate volume (ml)
Gleason score 
Biochemical recurrence (%)
Extraprostatic extension (%)
Positive margin (%)
Lymphovascular invasion (%)
Perineural invasion (%)
Distant metastasis (%)
66.71±5.6
25.29±2.1
10.45±6.1
40.55±17.7
  7.33±1.1
      5 (23.2)
    13 (61.9)
      2 (9.5)
      4 (19)
      8 (38)
      1 (4.7)
64.23±5.9
22.59±2.0
  7.67±4.0
36.33±17.0
  7.21±1.1
      2 (5.1)
    11 (28.2)
      2 (5.1)
      3 (7.6)
    10 (25)
      1 (2.5)
0.782
a
0.628
a
0.031
a
0.793
a
0.726
a
0.032
b
0.011
b
0.515
b
0.191
b
0.315
b
0.651
b
Values are presented as mean±SD or number (%). Group 1: preoperative serum testosterone ＜3 ng/ml, group 2: preoperative serum 
testosterone ≥3 ng/ml. 
BMI, body mass index; PSA, prostate-specific antigen. 
a: Student's t-test was applied for comparison of continuous variables, 
b: The Pearson chi-square test and Fisher exact test were used 
to compare categorical variables.
TABLE 3. Logistic regression analysis of the correlation between 
biochemical recurrence and each variable
Variables Odds ratio 95.0% CI p-value
Age (yr)
Pretreatment PSA (ng/ml)
Gleason score
Preoperative testosterone 
(≤3 ng/ml)
  0.836
  0.845
  0.829
13.649
0.706-1.989
0.571-1.250
0.370-1.861
1.661-2.431
0.057
0.399
0.650
0.015
PSA, prostate-specific antigen; CI, confidence interval. 
TABLE 4. Logistic regression analysis of the correlation between 
extraprostatic invasion and each variable
Variables Odds ratio 95.0% CI p-value
Age (yr)
Pretreatment PSA (ng/ml)
Gleason score
Preoperative testosterone 
  (≤3 ng/ml)
0.988
0.853
1.325
4.965
0.896-1.090
0.684-1.062
0.781-2.248
  1.418-17.384
0.816
0.155
0.297
0.012
PSA, prostate-specific antigen; CI, confidence interval. 
2.5%) (Table 2).
3. Correlation between biochemical recurrence and each 
variable
A low serum testosterone level (≤3 ng/ml) was associated 
with an increased risk of biochemical recurrence (odds ra-
tio [OR], 13.64; 95% confidence interval [CI], 1.66 to 2.43; 
p=0.015). The patients’ ages, preoperative PSA, and Glea-
son scores did not have a significant association with in-
creased risk of biochemical recurrence (p＞0.05) (Table 3).
4. Correlation between extraprostatic invasion and each 
variable
A low serum testosterone level (≤3 ng/ml) was associated 
with an increased risk of extraprostatic invasions (OR, 
4.96; 95% CI, 1.41 to 17.38; p=0.012). The patients’ ages, 
preoperative PSA, and Gleason scores did not have a sig-
nificant association with an increased risk of ex-
traprostatic invasions (p＞0.05) (Table 4).
DISCUSSION
In males, 90% of testosterone is generated in Leydig cells 
in the testes and the remaining 10% in the adrenal glands 
[9]. This testosterone is converted into the form of di-hy-
dro-testosterone (DHT). DHT works through androgen 
receptors to promote the growth of the prostate and plays 
important roles in the growth of male reproductive tissues 
in the testes and the prostate [10].
Since the first report of a relationship between serum tes-
tosterone and prostate cancer in 1941, many related stud-
ies have been conducted [11]. Adlercreutz et al. [12] found 
that the higher the value of mean serum testosterone, the 
better patients’ responses to hormone therapy in prostate 
cancer for the first time, and Chodak et al. [4] and Chen et 
al. [13] reported that patients with low preoperative testos-
terone showed poorer prognosis than did those with normal 
values and showed poorer responses to treatment. 
With regard to serum testosterone and prostate cancer 
stages, Massengill et al. [14] found that preoperative tes-
tosterone was lower in advanced localized prostate cancer 
(T3-4N0M0) cases than in localized prostate cancer (pT2) 
cases and suggested that low preoperative testosterone in 
localized prostate cancer was a predictive factor for ex-
traprostatic invasions. In the results of the present study 
also, 28.2% of the high preoperative testosterone group 
showed extraprostatic invasions, whereas 61.9% of the low 
preoperative testosterone group showed extraprostatic in-
vasions, which was a statistically significant difference be-
tween the two groups. Korean J Urol 2012;53:9-13
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Teloken et al. [15] reported that low preoperative testos-
terone was associated with positive surgical margins, but 
their study involved short follow-up periods and was con-
ducted with a small number of patients. In the present 
study also, there was no significant difference in positive 
surgical margins between the two groups. However, be-
cause surgical margins are greatly affected by surgical 
skills and surgeons’ experience, it is likely that simple com-
parison of these results is not very meaningful. Further-
more, Yamamoto et al. [16] examined the relationship be-
tween preoperative testosterone and lymphovascular in-
vasions, perineural invasions, and seminal vesical in-
vasions in 272 patients who underwent a radical prostatec-
tomy and reported that there was no particular association. 
No association was found in the present study either.
Yamamoto et al. [16] reported that BCR was more fre-
quent in patients with low preoperative testosterone. How-
ever, Zhang et al. [17] reported that low preoperative tes-
tosterone was not associated with BCR in patients who un-
derwent a radical prostatectomy, and the reason proposed 
by those authors was that this study included many pa-
tients with locally advanced BCR. In the present study, 
BCR was more frequent in patients with low preoperative 
testosterone (23.8% vs. 5.1%). 
Hoffman et al. [7] suggested that low preoperative testos-
terone was a predictive factor for high Gleason scores, and 
Schatzl et al. [18] reported high associations between low 
preoperative testosterone and high Gleason scores. How-
ever, Massengill et al. [14] examined 879 patients who un-
derwent a radical prostatectomy and reported that low pre-
operative testosterone values were not associated with 
Gleason scores. The results of the present study also 
showed no correlation between preoperative testosterone 
values and Gleason scores.
It is generally known that normal prostates produce pro-
tein materials such as PSA thanks to differentiated actions 
of androgen [19]. Morgentaler [20] suggested that testos-
terone values were low in hypogonadism patients and that 
the possibility of prostate cancer would be high if PSA val-
ues were 4.0 ng/ml or lower. Koo and Shim [21] examined 
120 patients with a PSA value of 10.0 ng/ml or higher who 
underwent a transrectal biopsy and reported that testos-
terone values at diagnosis were not associated with en-
hanced PSA values. In the present study, however, PSA 
values were higher in the group with low preoperative tes-
tosterone (10.45 ng/ml vs 7.67 ng/ml). This is considered to 
be because the number of subjects was small; thus, addi-
tional studies will be necessary.
Many hypotheses are being reported in relation to the 
mechanisms related to serum testosterone values, disease 
progression, and prognosis. There are hypotheses that re-
gard changes in testosterone values simply as secondary 
changes in chronic disease or disease progression and hy-
potheses that regard changes in testosterone values as 
negative feedback from the hypothalamic-pituitary-gona-
dal hormone axis.  Miller et al. [22] found that postoperative 
testosterone values increased in patients who underwent 
a prostatectomy and suggested that this indicated the pres-
ence of substances corresponding to negative feedback in 
prostate cancer cells. Currently, inhibin is considered to be 
a substance involved in this negative feedback mechanism 
through the hypothalamic-pituitary-gonadal hormone 
axis. Risbridger et al. [23] reported that higher inhibin val-
ues were associated with higher risks of biochemical recur-
rences in 174 patients who underwent a radical prostatec-
tomy due to prostate cancer. In animal experimental mod-
els, it was shown that inhibin was generated in the testis 
to suppress prostate and hypothalamic-pituitary secre-
tions [24,25]. Thus far, studies of inhibin have been limited 
to animal experiments and thus the roles of inhibin in hu-
man prostates are not yet clear. 
Large parts of the relationship between prostate cancer 
and testosterone are also not yet known. Freedland et al. 
[26] suggested that because serum testosterone does not af-
fect prostatic testosterone, it is impossible to predict the 
prognoses of prostate cancer with just the level of serum 
testosterone, and Marks et al. [27] suggested that ther-
apeutic testosterone administration in hypogonadism pa-
tients would not affect prostatic testosterone. Further-
more, there is a report that if finasteride, a 5a-reductase 
inhibitor, is used, although the overall incidence of prostate 
cancer will be reduced, the lowered prostatic testosterone 
will promote the growth of high-grade prostate cancer that 
is less affected by androgen and thus increase the risk of 
onset of high-grade prostate cancer [28,29]. Large-scale 
studies on a large number of patients will be necessary to 
clarify the relationship between testosterone and prostate 
cancer.
CONCLUSIONS
The incidence rates of extraprostatic invasions and bio-
chemical recurrences were significantly higher in the group 
with preoperative serum testosterone levels less than 3 
ng/ml Therefore, these results suggest that preoperative 
serum testosterone measurement will be helpful in pre-
dicting postoperative prostate cancer progression. 
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